London
15 °C
Manchester
14 °C
Glasgow
Dublin
16 °C
Belfast
Washington
Denver
17 °C
Atlanta
Dallas
20 °C
Houston Texas
New Orleans
19 °C
El Paso
Phoenix
Los Angeles
12 °C
-7 °C
-2 °C
25 °C
30 °C
Moderna announces positive results for Omicron vaccine / Photo: Joseph Prezioso - AFP
NYSE - LSE
| CMSC | -0.06% | 23.655 | $ | |
| AZN | 0.17% | 81.86 | $ | |
| NGG | 0.45% | 75.08 | $ | |
| SCS | -0.09% | 15.825 | $ | |
| BTI | 0.72% | 52.82 | $ | |
| GSK | 1.14% | 46.885 | $ | |
| BP | 1.64% | 35.45 | $ | |
| BCC | 1.63% | 69.47 | $ | |
| CMSD | -0.21% | 23.85 | $ | |
| RBGPF | 0% | 76 | $ | |
| RYCEF | -1.52% | 15.13 | $ | |
| BCE | -1.59% | 22.315 | $ | |
| RIO | -2.88% | 68.4 | $ | |
| JRI | -0.76% | 13.775 | $ | |
| VOD | -1.52% | 11.21 | $ | |
| RELX | -0.32% | 44.03 | $ |
Moderna announces positive results for Omicron vaccine
US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron.
This so-called "bivalent" vaccine was tested in a trial of more 850 adults, who had all received their first three doses of Moderna's original Spikevax vaccine.
Around half the group then received a fourth dose of Spikevax, while the rest received the bivalent vaccine.
Those who received the bivalent vaccine had significantly higher levels of neutralizing antibodies -- Y-shaped immune system proteins that block the virus -- against Omicron.
On average, these levels were around 75 percent higher in the group who got the bivalent vaccine as a fourth dose compared to those who got the original vaccine as a fourth dose. They also received slightly superior protection to the ancestral strain of Covid compared to Spikevax.
"We are thrilled," said Stephane Bancel, CEO of Moderna in a statement, adding he anticipated this vaccine would be the company's lead candidate for authorization as a booster this fall.
"We want to be as ready as early as August for shipping," he told investors in a call.
Stephen Hoge, the company's president, did concede that antibody levels would be lower against Omicron's sub variants that are now in circulation, but said he believed it was still a superior booster than repeating Spikevax.
The company doesn't yet have data on durability -- how the new vaccine booster will fare three months and six months out.
A panel of Food and Drug Administration experts will meet June 28 to discuss considerations and strategies for boosters in fall and winter.
Z.Garcia--PS
